RxDoctor Payments DataLook up a doctor →

Vladimir Klinov

Neurology · Manahawkin, NJNPI 1194764076

Payments from drug & device makers

$78,322in general payments, 2019–2025

Across 2,088 payments — averaging $37.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$53K
  • EMD Serono, Inc.$5K
  • UCB, Inc.$2K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$1K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)243$53,469
EMD Serono, Inc.229$4,696
UCB, Inc.173$1,708
Novartis174$1,515
Teva Pharmaceuticals USA, Inc.113$1,285
Biogen89$1,164
SK Life Science, Inc.56$1,000
Lilly USA, LLC65$990
Lundbeck LLC53$773
Bristol Myers Squibb67$755
AstraZeneca(2 entities)50$738
Neurelis, Inc.42$691
Sunovion Pharmaceuticals Inc.46$668
Genentech USA, Inc.35$632
Pfizer49$587
Jazz Pharmaceuticals Inc.39$542
Amgen(2 entities)43$526
Argenx US, Inc.34$518
E.r. Squibb & Sons, L.L.C.23$466
Livanova USA, Inc.18$447
Impel Pharmaceuticals Inc.27$431
Neurocrine Biosciences, Inc.31$346
Avanir Pharmaceuticals, Inc.36$326
Supernus Pharmaceuticals, Inc.74$309
Biohaven Pharmaceutical Holding Company Ltd.37$278
Eisai Inc.25$265
Sanofi20$250
Acorda Therapeutics, Inc17$247
Catalyst Pharmaceuticals, Inc.12$234
Biohaven Pharmaceuticals, Inc.25$225
Otsuka America Pharmaceutical, Inc.11$218
Acadia Pharmaceuticals Inc13$193
Johnson & Johnson(2 entities)9$155
Kyowa Kirin, Inc.11$153
Axsome Therapeutics, Inc.7$131
Amneal Pharmaceuticals LLC9$129
W. L. Gore & Associates, Inc.11$128
Boston Scientific7$125
Arbor Pharmaceuticals, Inc.6$95
Tanabe Pharma America, Inc.6$84
TG Therapeutics, Inc.4$69
Grifols USA, LLC5$69
Avion Pharmaceuticals5$64
Aquestive Therapeutics, Inc.4$62
Currax Pharmaceuticals LLC4$61
Upsher-smith Laboratories LLC4$57
Vanda Pharmaceuticals Inc.3$54
Akcea Therapeutics, Inc.3$50
Mallinckrodt Hospital Products Inc.2$49
Mallinckrodt Enterprises LLC3$41
Merz Pharmaceuticals, LLC2$37
CSL Behring2$27
Adamas Pharmaceuticals, Inc.2$25
Neuropace, Inc.1$21
Impel Pharmaceuticals LLC1$19
Scilex Pharmaceuticals Inc.1$19
Amylyx Pharmaceuticals, Inc.1$19
Springworks Therapeutics, Inc.1$18
Azurity Pharmaceuticals, Inc.1$16
Vertical Pharmaceuticals, LLC1$14

How this compares

$78,322 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$290,814
Medicare patients
701
Services billed
8,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Manahawkin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →